ACC 2019 In diabetes patients, use of dapagliflozine resulted in clinical benefit regardless of ejection fraction and CV death and total mortality were strongly reduced in HFrEF patients.
This video was recorded at the Congress of the American College of Cardiology (ACC) 2019.
Dr. Eri Kato is Cardiologist and researcher at the University of Kyoto in Japan.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- ACC.19Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events
Deepak L. Bhatt, MD